Aetna Offloads Business and 4 Stocks At 52-Week Highs
Actavis (NYSE:ACT): Closing price $92.46
The firm confirmed that it has filed an Abbreviated New Drug Application with the FDA, requesting approval to market Testosterone Gel, 1.62 percent. Actavis’s ANDA product is a generic version of AbbVie’s AndroGel 1.62 percent, which is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone. Shares closed up 0.38 perecnt on Monday to $92.46, and have been traded in a 52-week range of $65.70 to $92.37.